Live Attenuated Influenza Vaccine As a Nasal Model for Influenza Infection

Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Nov 12, 2019

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to study influenza, or the flu, by using a special nasal vaccine called the live attenuated influenza vaccine (LAIV). The goal is to create a nasal model that mimics an actual flu infection. Healthy adults aged 18 to 49 who have not yet received the flu vaccine for the 2019-2020 season may be eligible to participate. Participants will receive the LAIV and provide nasal samples so researchers can measure how the body responds to the vaccine and the virus.

If you decide to join the study, you can expect to have the nasal vaccine administered, and then some nasal samples will be taken to analyze your immune response. It's important to note that certain health conditions, like asthma or a weakened immune system, may prevent you from participating. This trial is currently recruiting participants, so if you or someone you know is interested and meets the criteria, it could be an opportunity to contribute to important research on influenza.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ages 18-49 years old,
• • not yet received influenza vaccine for 2019-2020, and
• • capable of giving signed informed consent.
• Exclusion Criteria:
• • Immunocompromising condition (e.g. HIV/AIDS, chemotherapy, immune suppressing medications),
• • active smoking within past 6 months,
• • asthma, chronic lung/liver/kidney /neurologic/hematologic/metabolic disorders,cardiovascular disease (excluding isolated hypertension), diabetes mellitus, disease, congestive heart failure,
• • pregnancy,
• • current or recent (within the past month) upper/lower respiratory tract infection, chronic sinusitis/nasal allergies requiring frequent or daily therapy (including topical corticosteroids),
• • prior adverse reaction to influenza vaccine,
• • history of Guillain-Barre syndrome,
• • egg allergy,
• • close contact with an individual with severe immunodeficiency/immunosuppression.